You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

LUMIFY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lumify patents expire, and what generic alternatives are available?

Lumify is a drug marketed by Bausch And Lomb Inc and is included in two NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in sixteen countries.

The generic ingredient in LUMIFY is brimonidine tartrate. There are eleven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lumify

A generic version of LUMIFY was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28th, 2003.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LUMIFY?
  • What are the global sales for LUMIFY?
  • What is Average Wholesale Price for LUMIFY?
Drug patent expirations by year for LUMIFY
Drug Prices for LUMIFY

See drug prices for LUMIFY

Recent Clinical Trials for LUMIFY

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Tulane UniversityPhase 4
University of LouisvillePhase 4
Bausch & Lomb IncorporatedPhase 3

See all LUMIFY clinical trials

Pharmacology for LUMIFY
Paragraph IV (Patent) Challenges for LUMIFY
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LUMIFY Ophthalmic Solution brimonidine tartrate 0.025% 208144 1 2021-07-12

US Patents and Regulatory Information for LUMIFY

LUMIFY is protected by four US patents.

Patents protecting LUMIFY


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS

Preferential vasoconstriction compositions and methods of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS

Compositions and methods for eye whitening
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc LUMIFY brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 208144-001 Dec 22, 2017 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb Inc LUMIFY PRESERVATIVE FREE brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 218424-001 Apr 19, 2024 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb Inc LUMIFY brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 208144-001 Dec 22, 2017 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb Inc LUMIFY brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 208144-001 Dec 22, 2017 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LUMIFY

See the table below for patents covering LUMIFY around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2819674 COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE LA MIGRAINE (COMPOSITIONS AND METHODS FOR THE TREATMENT OF MIGRAINE) ⤷  Sign Up
Slovenia 2320911 ⤷  Sign Up
European Patent Office 2515917 BRIMONIDINE POUR BLANCHIMENT DES YEUX (BRIMONIDINE FOR EYE WHITENING) ⤷  Sign Up
Spain 2550473 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LUMIFY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1631293 2014/041 Ireland ⤷  Sign Up PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293 300683 Netherlands ⤷  Sign Up PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293 14C0056 France ⤷  Sign Up PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293 2014C/042 Belgium ⤷  Sign Up PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.